ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab
Two studies were presented during the 2020 American Society of [...]
Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer
Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating [...]
Nivolumab for the treatment of metastatic non-clear cell renal cell carcinoma
Nivolumab alone and in combination with ipilimumab is used for [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
ASCO GU 2020: New drug, sitravatinib in combination with nivolumab for second-line treatment of advanced kidney cancer
The results from one of the first clinical trials of [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
C-reactive protein as a potential predictive biomarker for kidney cancer
A recent study published in Science Direct describes how a [...]
Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
PARP inhibitors, vaccines and combination therapies for kidney cancer
In this interview with OncLive, professor Sumanta Kumar Pal from [...]
